Cat. No.: HY-B1640

Ethacrynic acid

(Synonyms: Etacrynic acid)

10 Cited Publications

Customer Review

Based on 10 publication(s) in Google Scholar

Ethacrynic acid has anti-inflammatory and anticancer activity. Ethacrynic acid is an orally active diuretic. Ethacrynic acid is an inhibitor of glutathione S-transferase (GSTs) and Wnt signaling pathways. Ethacrynic acid is a radiosensitizer. Ethacrynic acid can inhibit airway smooth muscle (ASM) contraction in mice. Ethacrynic acid can increase the outflow of aqueous humor from the eye for the study of glaucoma.

For research use only. We do not sell to patients.

Purity: 99.90%
CAS No.: 58-54-8
Formula: C₁₃H₁₂Cl₂O₄
Molecular Weight:303.14

Storage:

4°C, protect from light

* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

Ethacrynic acid Chemical Structure

CAS No.: 58-54-8

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (10)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target

L-type calcium channel

All Wnt Isoforms :

All NF-κB Isoforms :

All Calcium Channel Isoforms :

All NO Synthase Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	84 μM Compound: 1, EA	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 22607679]
CHO-K1	EC₅₀	56 μM Compound: 1	Cytotoxicity against CHO-K1 cells by Alamar blue assay Cytotoxicity against CHO-K1 cells by Alamar blue assay	[PMID: 16962325]
HCT-116	IC₅₀	30.22 μM Compound: EA	Cytotoxic activity against human HCT116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Cytotoxic activity against human HCT116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 27156773]
HCT-116	IC₅₀	75 μM Compound: 1; EA	Antiproliferative activity against human HCT116 cells after 24 to 72 hrs by MTS assay Antiproliferative activity against human HCT116 cells after 24 to 72 hrs by MTS assay	[PMID: 27448922]
HL-60	GI₅₀	44.2 μM Compound: EA	Antiproliferative activity against human HL60 cells after 72 hrs Antiproliferative activity against human HL60 cells after 72 hrs	[PMID: 17287120]
HL-60	GI₅₀	44.2 μM Compound: EA	Growth inhibition of human HL60 cells after 72 hrs by trypan blue staining Growth inhibition of human HL60 cells after 72 hrs by trypan blue staining	[PMID: 22370342]
HL-60	GI₅₀	45 μM Compound: EA	Growth inhibition of human HL60 cells by hemocytometry Growth inhibition of human HL60 cells by hemocytometry	[PMID: 20055416]
HL-60	IC₅₀	3.4 μM Compound: EA	Inhibition of GST P1-1 in human HL60 cell lysate Inhibition of GST P1-1 in human HL60 cell lysate	[PMID: 20055416]
HL-60	IC₅₀	38 μM Compound: 1; EA	Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 24 hrs by MTS assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 24 hrs by MTS assay	[PMID: 27448922]
HL-60	IC₅₀	46 μM Compound: 1; EA	Antiproliferative activity against human HL60 cells after 24 to 72 hrs by MTS assay Antiproliferative activity against human HL60 cells after 24 to 72 hrs by MTS assay	[PMID: 27448922]
HT-1080	IC₅₀	54.53 μM Compound: EA	Cytotoxic activity against human HT1080 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Cytotoxic activity against human HT1080 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 27156773]
HT-29	IC₅₀	62.39 μM Compound: EA	Cytotoxic activity against human HT-29 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Cytotoxic activity against human HT-29 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 27156773]
KB	IC₅₀	11 μM Compound: 1; EA	Antiproliferative activity against human KB cells after 24 to 72 hrs by MTS assay Antiproliferative activity against human KB cells after 24 to 72 hrs by MTS assay	[PMID: 27448922]
MCF7	IC₅₀	28.92 μM Compound: EA	Cytotoxic activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Cytotoxic activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 27156773]
MCF7	IC₅₀	41 μM Compound: 1; EA	Antiproliferative activity against human MCF7 cells after 24 to 72 hrs by MTS assay Antiproliferative activity against human MCF7 cells after 24 to 72 hrs by MTS assay	[PMID: 27448922]
MDA-MB-231	IC₅₀	45.24 μM Compound: EA	Cytotoxic activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Cytotoxic activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 27156773]
MDA-MB-468	IC₅₀	81.45 μM Compound: EA	Cytotoxic activity against human MDA-MB-468 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Cytotoxic activity against human MDA-MB-468 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 27156773]
NCI-H1299	IC₅₀	44.29 μM Compound: EA	Cytotoxic activity against human H1299 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Cytotoxic activity against human H1299 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 27156773]
OVCAR-8	IC₅₀	72 μM Compound: 1; EA	Antiproliferative activity against human OVCAR8 cells after 24 to 72 hrs by MTS assay Antiproliferative activity against human OVCAR8 cells after 24 to 72 hrs by MTS assay	[PMID: 27448922]
PC-3	IC₅₀	75 μM Compound: 1; EA	Antiproliferative activity against human PC3 cells after 24 to 72 hrs by MTS assay Antiproliferative activity against human PC3 cells after 24 to 72 hrs by MTS assay	[PMID: 27448922]
SF-188	IC₅₀	31.65 μM Compound: EA	Cytotoxic activity against human SF188 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Cytotoxic activity against human SF188 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 27156773]
SK-BR-3	IC₅₀	34.21 μM Compound: EA	Cytotoxic activity against human SKBR3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Cytotoxic activity against human SKBR3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 27156773]
SK-OV-3	IC₅₀	>100 μM Compound: 1; EA	Antiproliferative activity against human SKOV3 cells after 24 to 72 hrs by MTS assay Antiproliferative activity against human SKOV3 cells after 24 to 72 hrs by MTS assay	[PMID: 27448922]
SW480	IC₅₀	32.7 μM Compound: 1	Inhibition of Wnt/beta-casein signaling in human SW480 cells by fluorimetry Inhibition of Wnt/beta-casein signaling in human SW480 cells by fluorimetry	[PMID: 19121941]

In Vitro

Ethacrynic acid (50 μM; 24 h) inhibits Wnt/β-catenin signaling in CLL cells^[1].
Ethacrynic acid (1-100 μM; 48 h) is cytotoxic in CLL cells with an IC₅₀ of 8.56 μM^[1].
Ethacrynic acid (0.01-0.25 mmol/L; 30 min) increases aqueous humor outflow facility acutely in eye and the outflow rate increases from 28% to 105%^[2].
Ethacrynic acid (10-100 μM; 30 min) can inhibit the activation of NF-κB pathway in RAW264.7 cells induced by LPS (100 ng/mL) and has anti-inflammatory activity^[3].
Ethacrynic acid (20 μM/mL; 2 h) can increase the radiation intensity in MCF-7 cancer cells after radiation exposure^[3].
Ethacrynic acid (100 μmol/L; 62.5-250 min) inhibits tracheal ring contraction induced by high -K⁺ (80 mmol/L) and acetylcholine (ACh, 100 µmol/L) in a dose-dependent manner with EC₅₀ of 40.28 µmol/L and 56.22 µmol/L, respectively^[8].
Ethacrynic acid (100 μmol/L; 500-2500 s) decreases the intracellular Ca²⁺ concentration induced by high -K⁺ and ACh from 0.40 to 0.16, 0.50 to 0.39, respectively^[8].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR^[1]

Cell Line:

Chronic lymphocytic leukemia (CLL)
Concentration:

1 μM, 10 μM, 100 μM
Incubation Time:

16 h
Result:

Depressed the expression of LEF-1, Cyclin D1 and Fibronectin in a concentration-dependent manner.( LEF-1, cyclin D1 and fibronectin are established target genes of the Wnt/b-catenin pathway).

Western Blot Analysis^[3]

Cell Line:

RAW 264.7
Concentration:

10 μM, 20 μM, 50 μM, 100 μM ;Before LPS treatment (100 ng/mL; 1 h)
Incubation Time:

30 min
Result:

Inhibited the expression of iNOS mRNA.
Inhibited degradation of IκBα and IκBβ.

In Vivo

Ethacrynic acid (450 μg/mouse; Oral gavage; Once daily for 60 days) can inhibit tumor growth in the mice^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Myeloma Balb/c mice model^[5]
Dosage:

450 μg/mouse
Administration:

Oral gavage (p.o.); Once daily for 60 days. After BALB/c mice were injected subcutaneously with 5 × 105 MPC11 myeloma cells.
Result:

Significantly inhibited tumor growth.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 58-54-8
Appearance Solid
Molecular Weight 303.14
Formula C₁₃H₁₂Cl₂O₄
Color White to off-white
SMILES

O=C(O)COC1=CC=C(C(C(CC)=C)=O)C(Cl)=C1Cl
Synonyms

Etacrynic acid
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

Publications (10)

All Bio/Physico-chemical AssayCell Imaging/StainingWBIn Vivo Efficacy StudyHistological Imaging/Staining

Sort by:

Journal Impact Factor

Autophagy

Inhibition of PINK1 senses ROS signaling to facilitate neuroblastoma cell pyroptosis. [Abstract]

2025 Mar 31. PMID: 40160153

Ethacrynic acid purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Mar 31. [Abstract]

Mito-ros levels measured with MitoSOX red using a flow cytometer of SH-SY5Y cells pretreated with 10 μM AC220 for 2 h followed by cotreatment with or without 75 μM Ethacrynic acid (EA) for 24 h. n = 5; mean ± S.D.

Ethacrynic acid purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Mar 31. [Abstract]

Representative microscopy images of SH-SY5Y cells pretreated with 10 μM AC220 for 2 h followed by cotreatment with or without 75 μM Ethacrynic acid (EA) for 24 h. Scale bar: 50 μm.

Ethacrynic acid purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Mar 31. [Abstract]

PI positive of SH-SY5Y cells pretreated with 10 μM AC220 for 2 h followed by cotreatment with or without 75 μM Ethacrynic acid (EA) for 24 h. Scale bar: 50 μm.

Ethacrynic acid purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Mar 31. [Abstract]

LDH release assay of SH-SY5Y cells pretreated with 10 μM AC220 for 2 h followed by cotreatment with or without 75 μM Ethacrynic acid (EA) for 24 h. Scale bar: 50 μm.

Ethacrynic acid purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Mar 31. [Abstract]

Immunoblotting analysis for GSDME cleavage and activation of SH-SY5Y cell lysates pretreated with 10 μM AC220 for 2 h followed by cotreatment with or without 75 μM Ethacrynic acid (EA) treatment for 24 h. TUBB was used as loading control.

Ethacrynic acid purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Mar 31. [Abstract]

Images of mice administered with AC220 (1.5 mg/kg), Ethacrynic acid (EA, 5 mg/kg, i.p. once daily) or AC220 (1.5 mg/kg) plus EA (5 mg/kg) every day.

Ethacrynic acid purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Mar 31. [Abstract]

Ethacrynic acid (EA, 5 mg/kg, i.p. once daily). luciferase signal intensities of tumors were quantified using bioluminescence imaging.

Ethacrynic acid purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Mar 31. [Abstract]

Ethacrynic acid (EA, 5 mg/kg, i.p. once daily). Images of SH-SY5Y orthotopic tumors. Scale bar: 1 cm.
Int J Biol Macromol

Reticuline isomerase AKR1B1 with aldo-keto reductase activity and detoxification function from the insect Blaps rhynchopetera. [Abstract]

2026 Mar:352:151224. PMID: 41791543
Free Radic Biol Med

Mifepristone protects acetaminophen induced liver injury through NRF2/GSH/GST mediated ferroptosis suppression. [Abstract]

2024 Jun 19:S0891-5849(24)00531-8. PMID: 38906233
J Med Chem

Don't Lose Your (War)head: Structure-Activity Relationships of Covalent Warheads as Substrates for GST-Catalyzed Glutathione Conjugation. [Abstract]

2026 May 14;69(9):11574-11591. PMID: 42062179
EMBO Rep

O-GlcNAcylation of TDP-43 suppresses proteinopathies and promotes TDP-43's mRNA splicing activity. [Abstract]

2021 Jun 4;22(6):e51649. PMID: 33855783
Int J Mol Sci

In Vivo Chemical Screening in Zebrafish Embryos Identified FDA-Approved Drugs That Induce Differentiation of Acute Myeloid Leukemia Cells. [Abstract]

2024 Jul 16;25(14):7798. PMID: 39063039
Life Sci Alliance

HCV poly U/UC sequence-induced inflammation leads to metabolic disorders in vulvar lichen sclerosis. [Abstract]

2021 Jun 18;4(8):e202000906. PMID: 34145025
Hear Res

Ethacrynic acid regulates gentamicin ototoxicity via the blood-labyrinth barrier. [Abstract]

2025 Aug 15:466:109405. PMID: 40865250
J Microbiol Biol Educ

Preliminary assessment of drug repurposing against virus-associated primary effusion lymphoma. [Abstract]

2025 Sep 25:e0021425. PMID: 40996285
Phytomedicine

Guhong injection mitigates myocardial ischemia/reperfusion injury by activating GST P to inhibit ASK1-JNK/p38 pathway. [Abstract]

2023 Jan:109:154603. PMID: 36610111

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (329.88 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 27.5 mg/mL (90.72 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.2988 mL

16.4940 mL

32.9881 mL

5 mM

0.6598 mL

3.2988 mL

6.5976 mL

10 mM

0.3299 mL

1.6494 mL

3.2988 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (8.25 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (8.25 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (8.25 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 1 mg/mL (3.30 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Lu D, et al. Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/beta-catenin pathway. PLoS One. 2009 Dec 14;4(12):e8294. [Content Brief]

[2]. Liang LL, et al. Ethacrynic acid increases facility of outflow in the human eye in vitro. Arch Ophthalmol. 1992 Jan;110(1):106-9. [Content Brief]

[3]. Han Y,et al. Ethacrynic acid inhibits multiple steps in the NF-kappaB signaling pathway. Shock. 2005 Jan;23(1):45-53. [Content Brief]

[4]. Khil MS, et al. Ethacrynic acid: a novel radiation enhancer in human carcinoma cells. Int J Radiat Oncol Biol Phys. 1996 Jan 15;34(2):375-80. [Content Brief]

[5]. Kim Y, et al. In vivo efficacy of the diuretic agent ethacrynic acid against multiple myeloma. Leuk Res. 2012 May;36(5):598-600. [Content Brief]

[6]. Li XQ, et al. Metabolism of Strained Rings: Glutathione S-transferase-Catalyzed Formation of a Glutathione-Conjugated Spiro-azetidine without Prior Bioactivation. Drug Metab Dispos. 2019 Nov;47(11):1247-1256. [Content Brief]

[7]. Harada T, et al. Ethacrynic acid decreases expression of proinflammatory intestinal wall cytokines and ameliorates gastrointestinal stasis in murine postoperative ileus. Clinics (Sao Paulo). 2018 Oct 18;73:e332. [Content Brief]

[8]. Zhao XX, et al. [Ethacrynic acid inhibits airway smooth muscle contraction in mice]. Sheng Li Xue Bao. 2019 Dec 25;71(6):863-873. Chinese. PMID: 31879742. [Content Brief]

[9]. Byun HJ, Kang KJ, Park MK, Lee HJ, Kang JH, Lee EJ, Kim YR, Kim HJ, Kim YW, Jung KC, Kim SY, Lee CH. Ethacrynic Acid Inhibits Sphingosylphosphorylcholine-Induced Keratin 8 Phosphorylation and Reorganization via Transglutaminase-2 Inhibition. Biomol Ther (Seoul). 2013 Sep 30;21(5):338-42. [Content Brief]

[10].

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	3.2988 mL	16.4940 mL	32.9881 mL	82.4701 mL
	5 mM	0.6598 mL	3.2988 mL	6.5976 mL	16.4940 mL
	10 mM	0.3299 mL	1.6494 mL	3.2988 mL	8.2470 mL
	15 mM	0.2199 mL	1.0996 mL	2.1992 mL	5.4980 mL
	20 mM	0.1649 mL	0.8247 mL	1.6494 mL	4.1235 mL
	25 mM	0.1320 mL	0.6598 mL	1.3195 mL	3.2988 mL
	30 mM	0.1100 mL	0.5498 mL	1.0996 mL	2.7490 mL
	40 mM	0.0825 mL	0.4124 mL	0.8247 mL	2.0618 mL
	50 mM	0.0660 mL	0.3299 mL	0.6598 mL	1.6494 mL
	60 mM	0.0550 mL	0.2749 mL	0.5498 mL	1.3745 mL
	80 mM	0.0412 mL	0.2062 mL	0.4124 mL	1.0309 mL
DMSO	100 mM	0.0330 mL	0.1649 mL	0.3299 mL	0.8247 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Ethacrynic acid

10 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Ethacrynic acid

Immunology/Inflammation Compound Library

Membrane Transporter/Ion Channel Compound Library

Metabolism/Protease Compound Library

Neuronal Signaling Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Calcium Channel Blocker Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cuproptosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Off-patent Drug Library

Mitochondrial Protection Compound Library

Antihypertensive Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

FDA-Approved Traditional Chinese Medicine Active Compound Library

Ion Channel Compound Library

Extracellular Vesicles (EVs) Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Amino Acid Metabolism Compound Library

Miao Ethnicity Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Ethacrynic acid

All Wnt Isoforms

All NF-κB Isoforms

All Calcium Channel Isoforms

All NO Synthase Isoforms

Biological Activity

Chemical Information

Publications (10)

Solvent & Solubility